Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits - Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent Duke University survey found that firms predominately conduct frequent visits to each clinical investigator site but "the rationale behind any specific monitoring approach does not appear to be evidence-based."

You may also be interested in...

Clinical Trials: US FDA Should Frame Risk-Based Monitoring As Best Practice, ACRO Says

Recent Q&A draft guidance is aimed at assisting sponsors in planning and conducting risk-based approaches to monitoring, but ACRO’s Doug Peddicord says agency needs to take a more straightforward, proactive approach to encouraging the move away from 100% source data verification.

Clinical Trial Monitoring Not Ready To Go Completely Off-Site, FDA Says

Agency yields to some, denies other industry requests in final guidance that declines to lay out one prescriptive monitoring path.

FDA Calculates Burden Of Producing Clinical Trial Monitoring Plans

The agency estimates that 88 sponsors will develop approximately 132 monitoring plans annually, as recommended in FDA’s draft guidance on oversight of clinical investigations; CDER will not be conducting prospective reviews of these plans but may do a pilot program in the future.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts